€3.2M European Grant awarded: a major boost for the launch of our validation study
June 11, 2018
Poster presentation on METAglut1™ our innovative IVD blood test at the meeting of SFNP 2019
January 16, 2019
February 2-4, 2022.
[EVENTS] Company ; METAglut1™
We are thrilled to share our experience at the 31st Congress of the Société Française de Neurologie Pédiatrique (SFNP), where we had the opportunity to present a poster detailing the results of our validation study for METAglut1™.
METAglut1™ is our first IVD blood test to aid the early diagnosis of Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, a rare metabolic disorder that can significantly impact the lives of affected children.
The congress of the SFNP (Société Française de Neurologie Pédiatrique) is a prominent congress dedicated to pediatric neurology, bringing together healthcare professionals, researchers, and experts in the field.
This annual event serves as a platform for discussing the latest advancements, sharing research findings, and fostering collaboration among specialists.
Participating in the SFNP 2022 has invigorated our commitment to advancing research and innovation in pediatric health. We are dedicated to collaborating with experts and stakeholders to improve patient outcomes and have the test as fast as possible covered and available.
